Susquehanna International Group
KTTA icon

Susquehanna International Group’s Pasithea Therapeutics KTTA Stock Holding History

Susquehanna International Group’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,928
Closed -$18.5K – 12867
2023
Q3 		$18.5K Buy
+1,928
New +$21.1K ﹤0.01% 11620
2023
Q2 		– Sell
-569
Closed -$4.42K – 12662
2023
Q1 		$4.42K Buy
+569
New +$6.43K ﹤0.01% 12318

Other funds holding KTTA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Susquehanna International Group's KTTA Position: Q4 2023 in Review

Susquehanna International Group sold out of Pasithea Therapeutics (KTTA) in Q4 2023, closing a stake of 1,928 shares — an estimated $18.5K sold.

Susquehanna International Group first reported a position in KTTA in Q1 2023 and held it in 2 quarters. The position peaked at $18.5K in Q3 2023. 8 funds tracked by Wall St. Rank hold KTTA as of Q4 2023.

  • Susquehanna International Group reported no remaining Pasithea Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Susquehanna International Group sold 1,928 Pasithea Therapeutics shares in Q4 2023, an estimated $18.5K.
  • Susquehanna International Group first reported a position in Pasithea Therapeutics in Q1 2023 and held it in 2 quarters.
  • Susquehanna International Group's Pasithea Therapeutics position peaked at $18.5K in Q3 2023.
  • 8 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q4 2023.

Based on Susquehanna International Group's 13F filing for Q4 2023, filed 14 Feb 2024.